- Home
- ELWS vs SBFM Comparison
ELWS vs SBFM Comparison
Compare ELWS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- SBFM
- Stock Information
- Founded
- ELWS 2018
- SBFM 2006
- Country
- ELWS Japan
- SBFM United States
- Employees
- ELWS N/A
- SBFM N/A
- Industry
- ELWS
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- SBFM Health Care
- Exchange
- ELWS Nasdaq
- SBFM Nasdaq
- Market Cap
- ELWS 6.2M
- SBFM 6.8M
- IPO Year
- ELWS 2023
- SBFM N/A
- Fundamental
- Price
- ELWS $2.57
- SBFM $2.45
- Analyst Decision
- ELWS
- SBFM Strong Buy
- Analyst Count
- ELWS 0
- SBFM 1
- Target Price
- ELWS N/A
- SBFM $15.00
- AVG Volume (30 Days)
- ELWS 15.5K
- SBFM 52.5K
- Earning Date
- ELWS 12-31-2024
- SBFM 03-27-2025
- Dividend Yield
- ELWS N/A
- SBFM N/A
- EPS Growth
- ELWS N/A
- SBFM N/A
- EPS
- ELWS N/A
- SBFM N/A
- Revenue
- ELWS $1,139,113.00
- SBFM $32,959,491.00
- Revenue This Year
- ELWS N/A
- SBFM $59.94
- Revenue Next Year
- ELWS N/A
- SBFM $164.69
- P/E Ratio
- ELWS N/A
- SBFM N/A
- Revenue Growth
- ELWS 285.14
- SBFM 61.94
- 52 Week Low
- ELWS $1.04
- SBFM $2.11
- 52 Week High
- ELWS $8.68
- SBFM $286.00
- Technical
- Relative Strength Index (RSI)
- ELWS 38.57
- SBFM 38.35
- Support Level
- ELWS $2.75
- SBFM $2.39
- Resistance Level
- ELWS $2.92
- SBFM $2.58
- Average True Range (ATR)
- ELWS 0.23
- SBFM 0.15
- MACD
- ELWS -0.06
- SBFM -0.01
- Stochastic Oscillator
- ELWS 2.09
- SBFM 14.89
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.